AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01209975 — intervention group
Intervention type: PROCEDURE
Intervention: Selective Laser Trabeculoplasty
Description: Patient will have selective laser trabeculoplasty as the first treatment for glaucoma. This treatment will be dictated clinically, since we do not assign the interventions.
Study NCT01920971 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: infrared therapy
Description: wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2
Study NCT01920971 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: infrared therapy
Description: wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2
Study NCT03508544 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar ESP block
Description: Lumbar ESP block will be performed at the begining of surgery under ganeral anesthesia. A convex ultrasound transducer will be placed in a longitudinal parasagittal orientation 4-6 cm lateral to L4 spinous process. The erector spinae muscles will be identified superficial to the tip of L4 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 40 mL of bupivacaine/lidocaine mixture will be injected.
Study NCT03508544 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QLB bLock
Description: QLB block will be performed at the begining of surgery under ganeral anesthesia. The convex transducer will be placed in the transverse plane on the flank of the patient cranial to the iliac crest.The 4th lumbar vertebral transverse process, erector spinae muscles, psoas muscles, transverse abdominis muscles, internal and external oblique muscles and the quadratus lumborum muscles will be identified. A 15cm 22G insulated needle will be inserted on the posterior corner of the convex probe. 40 ml of local anesthetic mixture(bupivacaine and lidocaine ) will be administered between the quadratus lumborum and psoas muscles into the fascial plane. We observed the local anesthetic pressing down on the psoas muscle in the ultrasound image.
Study NCT03508544 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
Study NCT03508544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
Study NCT02536157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermoplastic splinting
Study NCT02536157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermoplastic splinting
Study NCT01913171 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study NCT01574261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for four months
Study NCT01574261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inositol
Description: Inositol 4g/die for four months
Study NCT02099760 — intervention group
Intervention type: DEVICE
Intervention: STD testing (GC/Ct/trich)
Study NCT03132441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training for Frailty
Description: Cardiac Rehabilitation, abbreviated course
Study NCT01562678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: In the experimental arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject Liraglutide once per day for 18 days. Subjects will start the treatment with a dose of 0.6 mg for the first week, then 1.2 mg for the second week and 1.8 mg for 3 days in the third week.
Study NCT01562678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject placebo once per day for 18 days.
Study NCT00786097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacyd PH_DETINLYN (Lactic Acid)
Study NCT02070341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol
Study NCT02256020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheel-chair music aerobic exercise (WC-MAE)
Description: Wheel-chair music aerobic exercise with 3 times of 50-minute session a week for 6 months.
Study NCT02070341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picosalax
Study NCT02406716 — intervention group
Intervention type: OTHER
Intervention: Biospecimen retention
Study NCT02033655 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: > 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from lean pork.
Study NCT02033655 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet counseling and group education lessons
Description: Participants meet once a week for 6 months to participate in group lessons and counseling.
Study NCT03288129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: film-coated tablets
Study NCT02194244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1662 granules
Description: Single dose, oral administration of RG1662 immediate release granules
Study NCT02194244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RG1662 tablet
Description: Single dose, oral administration of film-coated RG1662 immediate release tablet
Study NCT02877381 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Revision Total Knee Arthroplasty (TKA)
Description: Femoral component exchange, tibial component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision TKA, randomization will be done to ensure equivalent numbers of each type of revision TKA between the treatment groups.
Study NCT02877381 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Revision Total Hip Arthroplasty (THA)
Description: Femoral component exchange, acetabulum component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision THA, randomization will be done to ensure equivalent numbers of each type of revision THA between the treatment groups.
Study NCT04380415 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Single lead ambulatory ECG patch
Description: Single lead ambulatory ECG patch worn on the chest
Study NCT02983344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Fascia iliaca compartment block using ropivacaine
Study NCT02983344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Intravenous fentanyl
Study NCT02983344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound-guided fascia iliaca compartment block
Study NCT02033655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet counseling and group education lessons
Description: Participants meet once a week for 6 months to participate in group lessons and counseling.
Study NCT03582267 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid (DHA)
Description: Daily administration of docosahexaenoic Acid (DHA). 2 grams of DHA liquid concentrate administered per day throughout trial period.
Study NCT04407624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Exercise
Description: Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. During the loading period, taking into consideration the heart rate, fatigue and shortness of breath, exercises such as walking, squat, limb movements with weights, stepping on the steps, walking on different floors are shown. Stretching exercises are done during the cooling period. Intermittent loading workouts will consist of 3-minute loads and 1-minute rest intervals. Participants are contacted every two weeks via communication methods such as e-mail, message and telephone conversation. Exercise diary is given to all patients and is taken from them at the end of the study.
Study NCT04407624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. In loading period, moderate aerobic exercise is consist of brisk walking to reach 60-85% of the person's maximum heart rate. Stretching exercises are done during the cooling period.
Study NCT03009149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise will perform 3 days per week
Study NCT02121444 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaferon, BAY 86-5046)
Study NCT02121444 — intervention group
Intervention type: DEVICE
Intervention: BETACONNECT auto-injector.
Study NCT01798511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasogastric Tube Feeding
Description: A nasogastric tube will be placed into the stomach of patients.
Study NCT01798511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Nutritonal Management
Description: Patients who are to have CNM will be on nil-by-mouth regimen until they either develop signs of severe AP (in which case nasojejunal tube feeding will be introduced) or the signs of AP mitigate (in which case clear liquids (as tolerated) followed by oral food (as tolerated) will be introduced)
Study NCT01979887 — intervention group
Intervention type: PROCEDURE
Intervention: Meibum Expression
Description: Meibum expression as per protocol. No investigational drug is administered in this study.
Study NCT03669822 — intervention group
Intervention type: OTHER
Intervention: Standard of care
Description: Care decisions driven by local physicians; this is an observational cohort.
Study NCT00718952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil
Description: vardenafil tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
Study NCT00718952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
Study NCT00718952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil
Description: Patients in all the 2 arms will take vardenafil tablet 5mg twice-daily orally from week 13 to week 24(open-label).
Study NCT00718952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vardenafil
Description: Patients in all the 2 arms will take vardenafil tablet 5mg twice-daily orally from week 13 to week 24(open-label).
Study NCT02862171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring-004
Description: To assess the safety profile of the 25 mg Dapivirine Vaginal Ring-004, when inserted at monthly intervals, in an open-label trial
Study NCT03615378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 5000 IU D3
Description: Daily
Study NCT03615378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1000 IU D3
Description: Daily
Study NCT03615378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose/sugar tablet
Study NCT05282862 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Horizontal bone augmentation
Description: Horizontal bone augmentation of a limited span (1-2 teeth) edentulous ridge with neighboring teeth present.
Study NCT05282862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Horizontal bone augmentation
Description: Horizontal bone augmentation of a limited span (1-2 teeth) edentulous ridge with neighboring teeth present.
Study NCT02473432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RMT + usual care
Description: Respiratory muscle training is performed with the Orygen Dual valve (inspiratory and espiratory trainer)
Study NCT02473432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NMES
Description: Neuromuscular electrical stimulation is performed with the Vital Stim ® device (approved by the FDA for dysphagia treatment). It consists in the placement of two electrodes located in suprahyoid muscles as above described.
Study NCT02473432 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Standard swallow therapy consists of physiotherapy, occupational therapy and speech therapy targeting specific swallow impairments. In the case of dysphagia, the standard pattern includes measures to protect the airway and compensatory techniques.
Study NCT02764060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue scraper
Description: The patients were instructed to start cleaning the tongue by two pulling strokes along the median sulcus of the tongue, followed by two pulling strokes along the lateral edges of the tongue.
Study NCT02764060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush
Description: The patients who were assigned to the tooth brush group were taught to perform three forward and backward strokes along the median sulcus and at each lateral part of the tongue.
Study NCT00844896 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DEF-only
Description: The DEF protocol is from the National Child Traumatic Stress Network (NCTSN). DEF provides a sequential methodology for clinicians to assess medically traumatized children and their families and to plan specific interventions for them.~In the present study, the DEF intervention is both a generalized approach taught to all Shriners Hospitals for Children (SHC)- Boston clinical staff, and for those participants of the present study, consists of an optional meeting with a member of the SHC Psychiatry Department. During this meeting, parents will have the chance to review any areas of pain, anxiety, or support that came up during their interviews or any other areas of concern about their child or his/her hospitalization that they wish to raise.
Study NCT00844896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DEF + COPE
Description: All enrolled participants will be offered the chance to meet with a psychiatric clinician for the DEF component of the intervention.~For those assigned to receive COPE (Creating Opportunities for Parent Empowerment), parents will receive one of two versions of the materials: one for children less than one year old, and one for children ages 1-5 years. The COPE program was adapted for children with burns and developed to target major stressors that parents experience when their children are hospitalized, such as the loss of parental control. COPE also contains a behavioral component to help parents to carry out the recommendations provided to them. Each of these versions of the COPE program is essentially self-administered to parents via audio tapes and activity workbooks.
Study NCT00701675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline 50 mg daily
Description: 50 mg daily
Study NCT00701675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline 100 mg daily
Description: 100 mg daily
Study NCT01603979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-203
Description: The antibody AV-203 is a humanized immunoglobulin G1/kappa (IgG1/κ) monoclonal antibody that targets the receptor tyrosine kinase (RTK) ERBB3 and inhibits ERBB3 activities. AV-203 will be administered as a 60 to 75-minute IV infusion once every 2 weeks until disease progression or unacceptable toxicity.
Study NCT03119441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Water Jet
Description: Dental Water Jet will be used by subjects to clean their teeth in the interproximal areas.
Study NCT03119441 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Floss
Description: Dental Floss will be used by subjects to clean their teeth in the interproximal areas.
Study NCT01451866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resistance training
Description: hypertrophic resistance training
Study NCT03210688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Tablet prednisolone
Study NCT03210688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Tablet prednisolone
Study NCT03210688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Description: Capsule alfacalcidol 0,5 microgram/day
Study NCT01776697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pelubiprofen (30mg) tablet IR
Study NCT01776697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pelubiprofen SR (as a pelubiprofen 90 mg) tablet
Study NCT02906566 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Retinol
Description: Retinol in the form of vitamin A lotion
Study NCT02906566 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo of Retinol
Study NCT01831401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operating table position 0° head down (Horizontal)
Study NCT01831401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operating table position 7° head down.
Study NCT01831401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operating table position Y° head down
Description: Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines).
Study NCT01451866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: complex resistance training
Description: complex resistance training with speed, excentric and power-endurance elements
Study NCT01831401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard straight acetabular component introducer without alignment guide.
Study NCT01831401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified 35° acetabular component introducer.
Study NCT01831401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inclinometer-assisted acetabular component introducer.
Study NCT00426361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix ® Polio
Description: One dose of vaccine administered intramuscularly
Study NCT00426361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)
Description: Three doses of vaccine administered intramuscularly, with the second and third dose give one month and six months after the first dose respectively
Study NCT01359969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhC1INH
Description: Patients up to 84 kg will receive one i.v. injection of Ruconest at a dose of 50 U/kg. The reconstituted solution should be administered as a slow i.v. injection over approximately 5 minutes. Patients of 84 kg body weight or greater will receive one i.v. injection of Ruconest at the dose of 4200 U (2 vials).
Study NCT02653430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Description: After complete exams such as EKG，UCG，spirometry and other basic exams,estimate the condition of patient whether he(she) can tolerate a surgical operation.Then we operate theSleeve gastrectomy laparoscopically by a group of experienced surgeons.
Study NCT02149108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib (BIBF 1120)
Study NCT02149108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02149108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BSC
Study NCT02149108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSC